MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
about
Solution Structures of a DNA Dodecamer Duplex with and without a Cisplatin 1,2-d(GG) Intrastrand Cross-Link: Comparison with the Same DNA Duplex Containing an Oxaliplatin 1,2-d(GG) Intrastrand Cross-Link † , ‡Flanking Bases Influence the Nature of DNA Distortion by Platinum 1,2-Intrastrand (GG) Cross-LinksMolecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder CancerReal-time monitoring of cisplatin-induced cell death.Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links.Oxaliplatin in the treatment of colorectal cancer.Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicityStructural basis for the sequence-dependent effects of platinum-DNA adducts.Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.MutS inhibits RecA-mediated strand exchange with platinated DNA substratesProteomics Analysis of Ovarian Cancer Cell Lines and Tissues Reveals Drug Resistance-associated Proteins.Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein.Synthesis, characterization and theoretical calculations of (1,2-diaminocyclohexane)(1,3-diaminopropane)gold(III) chloride complexes: in vitro cytotoxic evaluations against human cancer cell lines.Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.Synthesis, spectroscopic characterization, electrochemical behavior and computational analysis of mixed diamine ligand gold(III) complexes: antiproliferative and in vitro cytotoxic evaluations against human cancer cell lines.Towards the rational design of platinum(II) and gold(III) complexes as antitumour agents.Single-nucleotide polymorphisms of the Trypanosoma cruzi MSH2 gene support the existence of three phylogenetic lineages presenting differences in mismatch-repair efficiency.Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamicsEnhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells.Nano-selenium and its nanomedicine applications: a critical review.
P2860
Q27644753-40721064-AF5F-4614-BD89-CC9314807D6EQ27671829-ED286819-9F54-4DFE-8AAE-82AD73B16461Q28552735-B17F0F0B-C65F-4533-8B48-F8240D3D1F6FQ31014842-6A5048DC-3260-4492-B1EB-F160C83AEE51Q36296744-558BE54B-B7C9-4F02-800C-4942DCDB3BEBQ36788436-B4823777-BA50-445E-97E3-D27ECFD3DFFBQ37122036-7B78CE03-B33E-4A56-ABC2-3CE80A83F0BAQ37181475-C9A677F1-2265-4290-A2EF-4B65FA8FBB40Q37182939-D3A03041-09BE-457E-9FCF-66BA90EBF870Q37557482-0E9D4A96-716E-4FBA-9790-733D96BC740DQ37607909-852D913E-4C89-474C-B070-7AD3FF19E7F9Q38276429-9E6E3B2D-C7CC-4C6C-890E-98E1F1F2F3A7Q38356417-FBA0C9E6-6946-4179-B10F-46A972D8DB9CQ38861169-33E8A4A9-E791-4190-B6DA-7463192BEBA3Q38874680-A0CA9AC4-1450-471B-AD05-AE79B6765749Q38974568-23B28AD0-2A3C-4893-A8B3-70B64A06D4A3Q40003392-4E509814-3F31-434C-A193-CDFEFC6BAF74Q42067390-58B7E72B-745F-4AB7-876D-E5EF891D8103Q42789116-19E541C8-2569-4384-901D-59BCA9F46642Q49479651-00CBA8E5-BBA0-4EEC-A30B-0882833F4337Q52564739-CE1E80A8-5CF2-4B02-9D25-69E405D14AEE
P2860
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
@en
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
@nl
type
label
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
@en
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
@nl
prefLabel
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
@en
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
@nl
P2093
P2860
P356
P1476
MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA.
@en
P2093
Christine K Farinelli
Jill A Mello
John M Essigmann
Martin G Marinus
Zoran Z Zdraveski
P2860
P304
P356
10.1074/JBC.M105382200
P407
P577
2001-11-08T00:00:00Z